Home » About the AACR » Newsroom »
PHILADELPHIA – A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint...
PHILADELPHIA – In preclinical models, combining an investigational Aurora Kinase A (AURKA) inhibitor with a KRAS inhibitor or a...
PHILADELPHIA – Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinaseinhibitor, was feasible in treating...
PHILADELPHIA – In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young...
PHILADELPHIA – Black/African American patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide (Nubeqa) had...
Modifying criteria could help researchers enroll more Black patients in trials PHILADELPHIA – A simulated pancreatic cancer clinical trial...
PHILADELPHIA – Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival...
Data could help identify factors that contribute to higher risk PHILADELPHIA – Chinese Americans and Laotian Americans were over...
PHILADELPHIA – A pilot program that provided transgender men and nonbinary people with cervical cancer screening tailored to their...
Black patients experience higher lung cancer mortality than white patients, but equal access to immunotherapy may help close the...